

Table 1 Details of primary antibodies used in this study

Antibodies	Clone	Source	Dilution	Pretreatment
CD8	C8/144B	Maxim, Fuzhou, China	Pre-diluted	HIER
CD21	EP3093	Maxim	Pre-diluted	HIER
CD31	JC70A	Maxim	Pre-diluted	HIER
CD34	QBEnd/10	Maxim	Pre-diluted	HIER
CD68	KP-1	Maxim	Pre-diluted	Protease
F8	Polyclonal	Maxim	Pre-diluted	Protease
SMA	IA4	Maxim	Pre-diluted	N/A
S-100	4C4.9	Maxim	Pre-diluted	HIER
vimentin	SP20	Maxim	Pre-diluted	HIER
Desmin	D33	Maxim	Pre-diluted	N/A
ALK protein (CD246)	ALK-1	Dako, Glostrup, Denmark	1:50	HIER
NSE	Polyclonal	Maxim	Pre-diluted	N/A
EMA	E29	Maxim	Pre-diluted	N/A
ER	1D5	Maxim	Pre-diluted	HIER
PR	SP2	Maxim	Pre-diluted	HIER
AFP	Polyclonal	Maxim	Pre-diluted	N/A
IgG	Polyclonal	Dako	1:800	Protease
IgG4	EP4420	Abcam, Cambridge, UK	1:1000	HIER

N/A Not applicable, *HIER* heat induced epitope retrieval

Table 2 Clinicopathological features

Case	Age	Sex	Spleen weight(gm)	Mass size(cm)	Presentation	Original Diagnosis	Follow-up (months)
1	48	F	720	4	None	SANT	16, NER
2	35	F	658	3.5	None	SANT	48, NER
3	42	F	541	2	Anemia	Cavernous hemangioma	10, NER
4	32	F	432	3	Anemia	Cavernous hemangioma	132, NER

SANT sclerosing angiomatoid nodular transformation, *NER* no evidence of recurrence